期刊文献+

间充质干细胞上TNF-α受体在脓毒症急性肾损伤中的作用 被引量:5

The therapeutic effect of tumor necrosis factor alpha receptors on mesenchymal stem cells in acute kidney injury induced by endotoxin
下载PDF
导出
摘要 脓毒症急性肾损伤的发病率逐年上升,死亡率也逐年提高,寻求一种有效的治疗方法是目前的当务之急.间充质干细胞是一种多能干细胞,前期已有大量的实验证明,间充质干细胞用于治疗脓毒症急性肾损伤是有效的,并且也有相关证据表明TNF-α刺激后,可以加强间充质干细胞的这一作用.众所周知,TNF-α主要是与其相关受体结合以后方可发挥作用,MSC上同时存在TNFR1和TNFR2这两种受体,究竟是何种受体在治疗脓毒症急性肾损伤中发挥作用,就此作一综述. The incidence and mortality of sepsis induced acute kidney injury increased year by year, so seek an effective therapeutic method is the top priority currently.A large number of previous experiments have shown that multipotent mesenchymal stem cells had an protective effect on the treatment of sepsis induced acute kidney injury and TNF alpha can strength this protective effect.Proverbially,the TNF alpha can play a role in the acute renal failure mainly after associated with its receptors,and there are two kinds of receptors on mesenchymal stem cells such as tumor necrosis factor alpha receptor 1 and tumor necrosis factor alpha receptor 2.This article will give a summarization about which receptor plays a key role in the treatment of acute kidney injury induced by endotoxin.
出处 《暨南大学学报(自然科学与医学版)》 CAS CSCD 北大核心 2016年第5期363-366,371,共5页 Journal of Jinan University(Natural Science & Medicine Edition)
基金 深圳市科创委基础研究项目(JCYJ20160422151707152)
关键词 间充质干细胞 TNF-α受体 脓毒症急性肾损伤 内毒素脂多糖 mesenchymal stem cells tumor necrosis factor alpha receptors sepsis induced acute kidney injury lipopolysaccharide
  • 相关文献

参考文献4

二级参考文献85

  • 1Idriss HT,Naismith JH.TNF alpha and the TNF receptor superfamily:structure-function relationship[J].Micros Res 2000,50(3):184-195.
  • 2Barone D,Krantz C,Lambert D,et al.Comparative analysis of the ability of etanercept and infliximab to lyse TNE-expressing cells in a complement dependent fashion [J].Arthritis Rheum 1999,42:S369-375.
  • 3Peppel K,Crawford D,Beutler B,et al.A tumor necrosis factor (TNF) receptor-IgG heavy chain chimeric protein as a bivalent antagonist of TNF activity[J].J Exp Med 1991,174:1483-1489.
  • 4AderkaD,Engelmann H,Shemer-AvniI,et al.Variation in serum levels of the soluble TNF receptors among healthy individuals[J].Lymphokine Cytokine Res 1992,10:157-159.
  • 5Woley PH,Dutcher J,Widmer MB,et al.Influence of a recombinant human soluble tumor necrosis factor Fc fusion protein on type Ⅱ collagen-induced arthritis in mice[J].J Immunol 1993,151:6602 -6607.
  • 6Garrison L.McDonnell N D.Etanercept:therapeutic use in patients with rheumatoid arthritis[J].Ann Rheum Dis 1999,58(Suppl Ⅰ):165-169.
  • 7Lovell D J.Etanercept in children with polyarticular juvenile rheumatoid arthritis[J].New Engl J Med 2000,340:253-259.
  • 8Alldred A.Etanercept in rheumatoid arthritis[J].Expert Opin Pharmacother 2001,2(7):1137-1148.
  • 9ZeltserR,Valle L,Tanck c,et al.Clinical,histological,and immunophenotypic characteristics of injection site reactions associated with etanercept:a recombinant tumor necrosis factor alpha receptor:Fc fusion protein[J].Arch Dermatol 2001,137(7):893-899.
  • 10BaroneD,Krantz C,Lambert D,et al.Comparative analysis of the ability of etanercept and infliximab to lyse TNF-expressing cells in a complement dependent fashion [J].Arthritis Rheum 1999,42:S369-375.

共引文献39

同被引文献29

引证文献5

二级引证文献17

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部